May 6, 2020 / 12:21 PM / 20 days ago

BRIEF-Cabaletta Bio Receives FDA Fast Track Designation For DSG3-CAART For The Treatment Of Mucosal Pemphigus Vulgaris

May 6 (Reuters) - Cabaletta Bio Inc:

* CABALETTA BIO RECEIVES FDA FAST TRACK DESIGNATION FOR DSG3-CAART FOR THE TREATMENT OF MUCOSAL PEMPHIGUS VULGARIS

* CABALETTA BIO INC - FDA HAS GRANTED FAST TRACK DESIGNATION FOR DSG3-CAART (DESMOGLEIN 3 CHIMERIC AUTOANTIBODY RECEPTOR T CELLS)

* CABALETTA BIO - PLANS TO INITIATE PHASE 1 DESCAARTES TRIAL TO EVALUATE SAFETY & TOLERABILITY OF DSG3-CAART IN RELAPSED &/OR REFRACTORY PATIENTS IN 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below